Cargando…

Oprozomib in patients with newly diagnosed multiple myeloma

Detalles Bibliográficos
Autores principales:	Hari, Parameswaran, Matous, Jeffrey V., Voorhees, Peter M., Shain, Kenneth H., Obreja, Mihaela, Frye, John, Fujii, Hisaki, Jakubowiak, Andrzej J., Rossi, Davide, Sonneveld, Pieter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6697695/ https://www.ncbi.nlm.nih.gov/pubmed/31420532 http://dx.doi.org/10.1038/s41408-019-0232-6

Ejemplares similares

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
por: Landgren, Ola, et al.
Publicado: (2019)

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
por: Nooka, Ajay K., et al.
Publicado: (2022)

Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score
por: D’Agostino, Mattia, et al.
Publicado: (2021)

Body Mass Index and Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
por: Wang, Bei, et al.
Publicado: (2022)

Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma
por: Derman, Benjamin A., et al.
Publicado: (2022)

Extreme body mass index and survival in newly diagnosed multiple myeloma patients
por: Shah, Urvi A., et al.
Publicado: (2023)

Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients
por: Shah, Vallari, et al.
Publicado: (2020)

The prognostic value of the MASS in a multi-center cohort of patients with newly diagnosed multiple myeloma
por: Yang, Peiyu, et al.
Publicado: (2022)

High SOX2 expression is associated with poor survival in patients with newly diagnosed multiple myeloma
por: Shan, Xinhe, et al.
Publicado: (2023)

Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma
por: Leng, Siyang, et al.
Publicado: (2020)

Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect(®) MM Registry
por: Lee, Hans C., et al.
Publicado: (2021)

First-line treatment and survival of newly diagnosed primary plasma cell leukemia patients in the Netherlands: a population-based study, 1989-2018
por: Brink, Mirian, et al.
Publicado: (2021)

Validation of the 2(nd) Generation Proteasome Inhibitor Oprozomib for Local Therapy of Pulmonary Fibrosis
por: Semren, Nora, et al.
Publicado: (2015)

A Reliable and Effective UPLC-MS/MS Method for the Determination of Oprozomib in Rat Plasma
por: Li, Xia, et al.
Publicado: (2023)

Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation
por: Derman, Benjamin A., et al.
Publicado: (2021)

Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
por: Andersen, Kristian T., et al.
Publicado: (2020)

Prognostic value of the Second Revision of the International Staging System (R2-ISS) in a real-world cohort of patients with newly-diagnosed multiple myeloma
por: Yan, Wenqiang, et al.
Publicado: (2023)

Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma
por: Jakubowiak, Andrzej J, et al.
Publicado: (2022)

Genome-wide profiling of 5-hydroxymethylcytosines in circulating cell-free DNA reveals population-specific pathways in the development of multiple myeloma
por: Chiu, Brian C.-H., et al.
Publicado: (2022)

Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma
por: Dimopoulos, Meletios A., et al.
Publicado: (2020)

Impact of Comorbidities on Health-related Quality of Life in Nontransplant Eligible Patients With Newly Diagnosed Multiple Myeloma
por: Bennink, M. Christine, et al.
Publicado: (2022)

Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma
por: Vandewynckel, Yves-Paul, et al.
Publicado: (2016)

Socioeconomic disadvantage contributes to ethnic disparities in multiple myeloma survival: a matched cohort study
por: Buradagunta, Christopher Staffi, et al.
Publicado: (2022)

Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial
por: Mina, Roberto, et al.
Publicado: (2021)

Prolonged unfolded protein reaction is involved in the induction of chronic myeloid leukemia cell death upon oprozomib treatment
por: Wang, Fang, et al.
Publicado: (2020)

High prevalence of metabolic syndrome in women newly diagnosed with endometrial cancer
por: Kitson, Sarah J., et al.
Publicado: (2018)

Daratumumab in untreated newly diagnosed multiple myeloma
por: Abdallah, Nadine, et al.
Publicado: (2019)

Acquired platelet dysfunction in newly diagnosed myeloma
por: Mortimer, Joshua, et al.
Publicado: (2021)

A Focus on Newly Diagnosed Multiple Myeloma
por: Brigle, Kevin, et al.
Publicado: (2022)

Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis
por: Bonello, Francesca, et al.
Publicado: (2019)

Institutional factors associated with early mortality of newly diagnosed acute promyelocytic leukemia
por: Matsuda, Kensuke, et al.
Publicado: (2022)

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
por: San-Miguel, Jesus, et al.
Publicado: (2022)

Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma
por: Gavriatopoulou, Maria, et al.
Publicado: (2020)

Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma
por: Fonseca, Rafael, et al.
Publicado: (2020)

Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial
por: Biran, Noa, et al.
Publicado: (2021)

The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents
por: Romano, Alessandra, et al.
Publicado: (2017)

Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia
por: Jonas, Brian A., et al.
Publicado: (2022)

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance
por: Kumar, Shaji K., et al.
Publicado: (2019)

Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study
por: Brink, Mirian, et al.
Publicado: (2021)

Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma
por: Atrash, Shebli, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_44iogot2rmu1bffn1p22s6db70